Key result
Nisoldipine lowers blood pressure in hypertensive patients without altering pharmacokinetics or causing drug accumulation.
Why the study?
Does long-term nisoldipine treatment alter its pharmacokinetics or hemodynamic effects in patients with essential hypertension?
Population
6 patients with essential hypertension
Comparison
Nisoldipine vs Baseline (before oral treatment)
Design
Cohort
Follow-up
4 weeks
Authors
Loading...
May support chronic nisoldipine dosing in hypertension without accumulation; hypothesis-generating and requires larger randomized confirmation.
Does long-term nisoldipine treatment alter its pharmacokinetics or hemodynamic effects in patients with essential hypertension?
Long-term treatment with nisoldipine in hypertensive patients effectively lowers blood pressure without altering its own pharmacokinetics or causing drug accumulation.
Harten et al. (1989) studied essential hypertension (n=6). Nisoldipine vs. Baseline (before treatment) was evaluated on Pharmacokinetics (systemic clearance, terminal half-life, volume of distribution) and hemodynamic effects. Nisoldipine treatment for 4 weeks in hypertensive patients lowered blood pressure without significant changes in pharmacokinetic parameters (clearance, half-life, volume of distribution) or accumulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: